HRP20100250T1 - Heterociklički kondenzirani spojevi upotrebljivi kao antidiuretski agensi - Google Patents
Heterociklički kondenzirani spojevi upotrebljivi kao antidiuretski agensi Download PDFInfo
- Publication number
- HRP20100250T1 HRP20100250T1 HR20100250T HRP20100250T HRP20100250T1 HR P20100250 T1 HRP20100250 T1 HR P20100250T1 HR 20100250 T HR20100250 T HR 20100250T HR P20100250 T HRP20100250 T HR P20100250T HR P20100250 T1 HRP20100250 T1 HR P20100250T1
- Authority
- HR
- Croatia
- Prior art keywords
- oxo
- carbonyl
- dihydro
- methyl
- fluoro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 24
- 125000000623 heterocyclic group Chemical group 0.000 title claims 2
- 229940124538 antidiuretic agent Drugs 0.000 title abstract 2
- 239000003160 antidiuretic agent Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 208000004880 Polyuria Diseases 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 208000008967 Enuresis Diseases 0.000 claims 3
- 206010046543 Urinary incontinence Diseases 0.000 claims 3
- 201000010064 diabetes insipidus Diseases 0.000 claims 3
- 208000031169 hemorrhagic disease Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 206010029446 nocturia Diseases 0.000 claims 3
- 208000005346 nocturnal enuresis Diseases 0.000 claims 3
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims 2
- 208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 208000028235 central diabetes insipidus Diseases 0.000 claims 2
- 201000005119 neurohypophyseal diabetes insipidus Diseases 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- CCVLBNBMRMPHMI-UHFFFAOYSA-N 2-[5,6-difluoro-4-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methylcarbamoyl]-2-oxo-3h-quinoxalin-1-yl]acetic acid Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C(F)=CC=C3N(CC(O)=O)C(=O)C2)C(C)=C1 CCVLBNBMRMPHMI-UHFFFAOYSA-N 0.000 claims 1
- JONRRARSASBCMZ-UHFFFAOYSA-N 2-[5-chloro-4-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methylcarbamoyl]-2-oxo-3h-quinoxalin-1-yl]acetic acid Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(Cl)C=CC=C3N(CC(O)=O)C(=O)C2)C(C)=C1 JONRRARSASBCMZ-UHFFFAOYSA-N 0.000 claims 1
- VAXRYTAALHNBRJ-UHFFFAOYSA-N 2-[5-fluoro-4-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methylcarbamoyl]-2-oxo-3h-quinoxalin-1-yl]acetic acid Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3N(CC(O)=O)C(=O)C2)C(C)=C1 VAXRYTAALHNBRJ-UHFFFAOYSA-N 0.000 claims 1
- KTFNHAAEJKRKSX-UHFFFAOYSA-N 2-[6-fluoro-5-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methylcarbamoyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-1-yl]acetic acid Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3N(CC(O)=O)C(=O)CC2)C(C)=C1 KTFNHAAEJKRKSX-UHFFFAOYSA-N 0.000 claims 1
- TUJFLCMFELHJJM-UHFFFAOYSA-N 4-(3-aminopropyl)-8-fluoro-n-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3N(CCCN)C(=O)C2)C(C)=C1 TUJFLCMFELHJJM-UHFFFAOYSA-N 0.000 claims 1
- RTGRLAOKMUTYPS-UHFFFAOYSA-N 4-(cyanomethyl)-8-fluoro-3-oxo-2h-quinoxaline-1-carboxylic acid Chemical compound C1=CC(F)=C2N(C(=O)O)CC(=O)N(CC#N)C2=C1 RTGRLAOKMUTYPS-UHFFFAOYSA-N 0.000 claims 1
- QYCNNJCTHIQWOH-UHFFFAOYSA-N 4-(cyanomethyl)-n-[[4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)-2-methylphenyl]methyl]-8-fluoro-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1C2=CC=CN2CC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3N(CC#N)C(=O)C2)C(C)=C1 QYCNNJCTHIQWOH-UHFFFAOYSA-N 0.000 claims 1
- WNKRJOPPAOUEMF-UHFFFAOYSA-N 6-fluoro-1-(2-hydroxyethyl)-n-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepine-5-carboxamide Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3N(CCO)C(=O)CC2)C(C)=C1 WNKRJOPPAOUEMF-UHFFFAOYSA-N 0.000 claims 1
- JUAZRQSBTZDRHE-UHFFFAOYSA-N 7,8-difluoro-4-(2-hydroxyethyl)-n-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C(F)=CC=C3N(CCO)C(=O)C2)C(C)=C1 JUAZRQSBTZDRHE-UHFFFAOYSA-N 0.000 claims 1
- GWIIEHJWBUHFEU-UHFFFAOYSA-N 8-chloro-4-(2-hydroxyethyl)-n-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(Cl)C=CC=C3N(CCO)C(=O)C2)C(C)=C1 GWIIEHJWBUHFEU-UHFFFAOYSA-N 0.000 claims 1
- CPOALOHYYXNNNA-UHFFFAOYSA-N 8-fluoro-4-(2-hydroxyethyl)-n-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3N(CCO)C(=O)C2)C(C)=C1 CPOALOHYYXNNNA-UHFFFAOYSA-N 0.000 claims 1
- OTZUILVAXOYUFF-UHFFFAOYSA-N 8-fluoro-4-[2-(methylamino)ethyl]-n-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C(C=C1C)=CC=C1CNC(=O)N1CC(=O)N(CCNC)C2=CC=CC(F)=C21 OTZUILVAXOYUFF-UHFFFAOYSA-N 0.000 claims 1
- JCPMZMJTSPCICG-UHFFFAOYSA-N 8-fluoro-n-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]-3-oxo-4-(2-oxoethyl)-2h-quinoxaline-1-carboxamide Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3N(CC=O)C(=O)C2)C(C)=C1 JCPMZMJTSPCICG-UHFFFAOYSA-N 0.000 claims 1
- LUBNUULPTHIVIL-UHFFFAOYSA-N 8-fluoro-n-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]-3-oxo-4-(2h-tetrazol-5-ylmethyl)-2h-quinoxaline-1-carboxamide Chemical compound CC1=CC(C(=O)N2C3=CC=CC=C3CCCC2)=CC=C1CNC(=O)N(C1=C(F)C=CC=C11)CC(=O)N1CC1=NN=NN1 LUBNUULPTHIVIL-UHFFFAOYSA-N 0.000 claims 1
- GZQGMVHITXMWEQ-UHFFFAOYSA-N 8-fluoro-n-[[4-[[2-(furan-2-yl)phenyl]methylcarbamoyl]-2-methylphenyl]methyl]-4-(2-hydroxyethyl)-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C=1C=C(CNC(=O)N2C3=C(F)C=CC=C3N(CCO)C(=O)C2)C(C)=CC=1C(=O)NCC1=CC=CC=C1C1=CC=CO1 GZQGMVHITXMWEQ-UHFFFAOYSA-N 0.000 claims 1
- XRUQLOXTQOWTMD-UHFFFAOYSA-N 9-fluoro-n-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]-5-oxo-2,3-dihydro-4,1-benzoxazepine-1-carboxamide Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3C(=O)OCC2)C(C)=C1 XRUQLOXTQOWTMD-UHFFFAOYSA-N 0.000 claims 1
- YTANYUHLLLYFRR-UHFFFAOYSA-N 9-fluoro-n-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]-5-oxo-3,4-dihydro-2h-1,4-benzodiazepine-1-carboxamide Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3C(=O)NCC2)C(C)=C1 YTANYUHLLLYFRR-UHFFFAOYSA-N 0.000 claims 1
- 125000006416 CBr Chemical group BrC* 0.000 claims 1
- RPZZYEXZZBNXAP-UHFFFAOYSA-N CC1=C(CN)C=CC(C(N(C)C(C=CC=C2)=C2C2=CC=CS2)=O)=C1.OCCN(C(C1)=O)C2=CC=CC(F)=C2N1C(O)=O Chemical compound CC1=C(CN)C=CC(C(N(C)C(C=CC=C2)=C2C2=CC=CS2)=O)=C1.OCCN(C(C1)=O)C2=CC=CC(F)=C2N1C(O)=O RPZZYEXZZBNXAP-UHFFFAOYSA-N 0.000 claims 1
- 125000006414 CCl Chemical group ClC* 0.000 claims 1
- 125000006415 CF Chemical group FC* 0.000 claims 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- ATESYFRDSCVDKU-UHFFFAOYSA-N [4-(aminomethyl)-3-methylphenyl]-[1-(2-hydroxyethyl)-3,4-dihydro-2h-1,5-benzodiazepin-5-yl]methanone Chemical compound C1=C(CN)C(C)=CC(C(=O)N2C3=CC=CC=C3N(CCO)CCC2)=C1 ATESYFRDSCVDKU-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- LANLESWXWIGXJH-UHFFFAOYSA-N ethyl 2-[1-[[4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)-2-methylphenyl]methylcarbamoyl]-8-fluoro-3,4-dihydro-2h-quinolin-4-yl]acetate Chemical compound C1C2=CC=CN2CC2=CC=CC=C2N1C(=O)C(C=C1C)=CC=C1CNC(=O)N1CCC(CC(=O)OCC)C2=CC=CC(F)=C21 LANLESWXWIGXJH-UHFFFAOYSA-N 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- XQDIIKFTPCVKOL-UHFFFAOYSA-N methyl 2-[4-[[4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)-2-methylphenyl]methylcarbamoyl]-5-fluoro-2-oxo-3h-quinoxalin-1-yl]acetate Chemical compound C1C2=CC=CN2CC2=CC=CC=C2N1C(=O)C(C=C1C)=CC=C1CNC(=O)N1CC(=O)N(CC(=O)OC)C2=CC=CC(F)=C21 XQDIIKFTPCVKOL-UHFFFAOYSA-N 0.000 claims 1
- GAJPQMVBBSNBBD-UHFFFAOYSA-N n-[[2-chloro-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]-8-fluoro-3-oxo-2,4-dihydroquinoxaline-1-carboxamide Chemical compound C1CCCC2=CC=CC=C2N1C(=O)C(C=C1Cl)=CC=C1CNC(=O)N1CC(=O)NC2=C1C(F)=CC=C2 GAJPQMVBBSNBBD-UHFFFAOYSA-N 0.000 claims 1
- MVUBNLGNDAPHTF-UHFFFAOYSA-N n-[[4-(3,4-dihydro-2h-1,5-benzoxazepine-5-carbonyl)-2-methylphenyl]methyl]-8-fluoro-4-(2-hydroxyethyl)-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1CCOC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3N(CCO)C(=O)C2)C(C)=C1 MVUBNLGNDAPHTF-UHFFFAOYSA-N 0.000 claims 1
- VXYSNVYMTOLJCL-UHFFFAOYSA-N n-[[4-(4,10-dihydropyrazolo[5,1-c][1,4]benzodiazepine-5-carbonyl)-2-methylphenyl]methyl]-8-fluoro-4-methyl-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1C2=CC=NN2CC2=CC=CC=C2N1C(=O)C(C=C1C)=CC=C1CNC(=O)N1CC(=O)N(C)C2=CC=CC(F)=C21 VXYSNVYMTOLJCL-UHFFFAOYSA-N 0.000 claims 1
- GFXSGMWMKBFBCB-UHFFFAOYSA-N n-[[4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)-2-methylphenyl]methyl]-7,8-difluoro-4-(2-hydroxyethyl)-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1C2=CC=CN2CC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C(F)=CC=C3N(CCO)C(=O)C2)C(C)=C1 GFXSGMWMKBFBCB-UHFFFAOYSA-N 0.000 claims 1
- BKBPRHPGHDJBEZ-UHFFFAOYSA-N n-[[4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)-2-methylphenyl]methyl]-8-fluoro-3,4-dihydro-2h-quinoline-1-carboxamide Chemical compound C1C2=CC=CN2CC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3CCC2)C(C)=C1 BKBPRHPGHDJBEZ-UHFFFAOYSA-N 0.000 claims 1
- JZXICTOVGTUPGV-UHFFFAOYSA-N n-[[4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)-2-methylphenyl]methyl]-8-fluoro-4-(2-hydroxyethyl)-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1C2=CC=CN2CC2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3N(CCO)C(=O)C2)C(C)=C1 JZXICTOVGTUPGV-UHFFFAOYSA-N 0.000 claims 1
- GLRQXRYANPFDCN-UHFFFAOYSA-N n-[[4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)-2-methylphenyl]methyl]-8-fluoro-4-(2-methoxyethyl)-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1C2=CC=CN2CC2=CC=CC=C2N1C(=O)C(C=C1C)=CC=C1CNC(=O)N1CC(=O)N(CCOC)C2=CC=CC(F)=C21 GLRQXRYANPFDCN-UHFFFAOYSA-N 0.000 claims 1
- YPFJBDHVHYWQRW-UHFFFAOYSA-N n-[[4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)-2-methylphenyl]methyl]-8-fluoro-4-methyl-3-oxo-2h-quinoxaline-1-carboxamide Chemical compound C1C2=CC=CN2CC2=CC=CC=C2N1C(=O)C(C=C1C)=CC=C1CNC(=O)N1CC(=O)N(C)C2=CC=CC(F)=C21 YPFJBDHVHYWQRW-UHFFFAOYSA-N 0.000 claims 1
- JUJUEOPMXBWCIC-UHFFFAOYSA-N n-[[4-(6,7-dihydrobenzo[d][1]benzazepine-5-carbonyl)-2-methylphenyl]methyl]-8-fluoro-3-oxo-2,4-dihydroquinoxaline-1-carboxamide Chemical compound C1CC2=CC=CC=C2C2=CC=CC=C2N1C(=O)C1=CC=C(CNC(=O)N2C3=C(F)C=CC=C3NC(=O)C2)C(C)=C1 JUJUEOPMXBWCIC-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 102000004136 Vasopressin Receptors Human genes 0.000 abstract 1
- 108090000643 Vasopressin Receptors Proteins 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60289004P | 2004-08-20 | 2004-08-20 | |
| EP04104006A EP1627876A1 (en) | 2004-08-20 | 2004-08-20 | Heterocyclic condensed compounds useful as antidiuretic agents |
| PCT/EP2005/054081 WO2006018443A1 (en) | 2004-08-20 | 2005-08-18 | Heterocyclic condensed compounds useful as antidiuretic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100250T1 true HRP20100250T1 (hr) | 2010-06-30 |
Family
ID=34929464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100250T HRP20100250T1 (hr) | 2004-08-20 | 2010-05-03 | Heterociklički kondenzirani spojevi upotrebljivi kao antidiuretski agensi |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8063038B2 (es) |
| EP (2) | EP1627876A1 (es) |
| JP (1) | JP4705105B2 (es) |
| KR (1) | KR100877336B1 (es) |
| CN (1) | CN1968947A (es) |
| AT (1) | ATE457026T1 (es) |
| AU (1) | AU2005273875B2 (es) |
| CA (1) | CA2567782A1 (es) |
| CY (1) | CY1110619T1 (es) |
| DE (1) | DE602005019241D1 (es) |
| DK (1) | DK1778677T3 (es) |
| ES (1) | ES2339786T3 (es) |
| HK (1) | HK1100290A1 (es) |
| HR (1) | HRP20100250T1 (es) |
| IL (1) | IL178839A0 (es) |
| MX (1) | MX2007001861A (es) |
| NO (1) | NO20071476L (es) |
| PL (1) | PL1778677T3 (es) |
| PT (1) | PT1778677E (es) |
| RU (1) | RU2359969C2 (es) |
| SI (1) | SI1778677T1 (es) |
| WO (1) | WO2006018443A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| CA2685860A1 (en) | 2007-05-10 | 2008-11-20 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| DK2303021T3 (en) | 2008-06-16 | 2019-04-08 | Univ Tennessee Res Found | RELATIONSHIPS FOR TREATING CANCER |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| BRPI0915761A2 (pt) * | 2008-07-16 | 2015-11-03 | Hoffmann La Roche | composto de heterociclila para tratamento de doença cardiovascular |
| WO2011005842A1 (en) | 2009-07-09 | 2011-01-13 | Gilead Sciences, Inc. | Anti-rsv compounds |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| JP5879273B2 (ja) | 2010-03-01 | 2016-03-08 | ジーティーエックス・インコーポレイテッド | 癌を処置するための化合物 |
| US9119878B2 (en) | 2010-07-08 | 2015-09-01 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| MX2014008284A (es) * | 2012-01-04 | 2015-03-03 | Wellesley Pharmaceutical Llc | Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta. |
| EP2612662B1 (en) * | 2012-01-04 | 2020-03-04 | Wellesley Pharmaceuticals, LLC | Delayed-release formulation for reducing the frequency of urination and method of use thereof |
| CA2856677A1 (en) * | 2012-01-04 | 2013-07-11 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| EP2612663A1 (en) * | 2012-01-04 | 2013-07-10 | Wellesley Pharmaceuticals, LLC | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| EP2827852A4 (en) * | 2012-03-19 | 2016-03-02 | Wellesley Pharmaceuticals Llc | EXTENDED RELEASE FORMULATION FOR REDUCING BUBBLE HEAT FREQUENCY AND METHOD FOR USE THEREOF |
| US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| JPWO2014208296A1 (ja) * | 2013-06-25 | 2017-02-23 | イハラケミカル工業株式会社 | ニトロベンゼン化合物を製造する方法 |
| CN106810508B (zh) * | 2017-01-05 | 2019-12-10 | 浙江农林大学暨阳学院 | 一种铁催化多组分反应合成苯并[1,4]-氧氮杂卓化合物的方法 |
| WO2019003433A1 (ja) | 2017-06-30 | 2019-01-03 | 大塚製薬株式会社 | ベンゾアゼピン誘導体 |
| CN114853728B (zh) * | 2022-05-07 | 2023-11-07 | 四川制药制剂有限公司 | 一种富马酸伏诺拉生片及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0015601D0 (en) * | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
-
2004
- 2004-08-20 EP EP04104006A patent/EP1627876A1/en not_active Withdrawn
-
2005
- 2005-08-18 PL PL05781746T patent/PL1778677T3/pl unknown
- 2005-08-18 EP EP05781746A patent/EP1778677B1/en active Active
- 2005-08-18 CA CA002567782A patent/CA2567782A1/en not_active Abandoned
- 2005-08-18 US US11/660,207 patent/US8063038B2/en not_active Expired - Fee Related
- 2005-08-18 AT AT05781746T patent/ATE457026T1/de active
- 2005-08-18 SI SI200530930T patent/SI1778677T1/sl unknown
- 2005-08-18 ES ES05781746T patent/ES2339786T3/es active Active
- 2005-08-18 WO PCT/EP2005/054081 patent/WO2006018443A1/en active Application Filing
- 2005-08-18 JP JP2007526462A patent/JP4705105B2/ja not_active Expired - Fee Related
- 2005-08-18 DE DE602005019241T patent/DE602005019241D1/de active Active
- 2005-08-18 AU AU2005273875A patent/AU2005273875B2/en not_active Ceased
- 2005-08-18 MX MX2007001861A patent/MX2007001861A/es active IP Right Grant
- 2005-08-18 CN CNA2005800192975A patent/CN1968947A/zh active Pending
- 2005-08-18 RU RU2007101237/04A patent/RU2359969C2/ru not_active IP Right Cessation
- 2005-08-18 PT PT05781746T patent/PT1778677E/pt unknown
- 2005-08-18 KR KR1020077002387A patent/KR100877336B1/ko not_active IP Right Cessation
- 2005-08-18 DK DK05781746.2T patent/DK1778677T3/da active
-
2006
- 2006-10-24 IL IL178839A patent/IL178839A0/en unknown
-
2007
- 2007-03-19 NO NO20071476A patent/NO20071476L/no not_active Application Discontinuation
- 2007-08-01 HK HK07108386.8A patent/HK1100290A1/xx not_active IP Right Cessation
-
2010
- 2010-04-26 CY CY20101100370T patent/CY1110619T1/el unknown
- 2010-05-03 HR HR20100250T patent/HRP20100250T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2339786T3 (es) | 2010-05-25 |
| JP4705105B2 (ja) | 2011-06-22 |
| US20080234250A1 (en) | 2008-09-25 |
| EP1778677A1 (en) | 2007-05-02 |
| DK1778677T3 (da) | 2010-04-19 |
| HK1100290A1 (en) | 2007-09-14 |
| AU2005273875B2 (en) | 2009-08-27 |
| DE602005019241D1 (de) | 2010-03-25 |
| IL178839A0 (en) | 2007-03-08 |
| CA2567782A1 (en) | 2006-02-23 |
| AU2005273875A1 (en) | 2006-02-23 |
| WO2006018443A1 (en) | 2006-02-23 |
| RU2007101237A (ru) | 2008-09-27 |
| US8063038B2 (en) | 2011-11-22 |
| SI1778677T1 (sl) | 2010-09-30 |
| NO20071476L (no) | 2007-03-19 |
| RU2359969C2 (ru) | 2009-06-27 |
| CY1110619T1 (el) | 2015-04-29 |
| KR20070027761A (ko) | 2007-03-09 |
| ATE457026T1 (de) | 2010-02-15 |
| MX2007001861A (es) | 2007-04-24 |
| EP1778677B1 (en) | 2010-02-03 |
| EP1627876A1 (en) | 2006-02-22 |
| JP2008509972A (ja) | 2008-04-03 |
| KR100877336B1 (ko) | 2009-01-07 |
| PL1778677T3 (pl) | 2010-07-30 |
| PT1778677E (pt) | 2010-03-17 |
| CN1968947A (zh) | 2007-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100250T1 (hr) | Heterociklički kondenzirani spojevi upotrebljivi kao antidiuretski agensi | |
| CA1285564C (en) | 1-heteroaryl-4-¬(2,5-pyrrolidinedion-1-yl)alkyl|piperazine derivatives | |
| ES2296763T3 (es) | Pirrolidinas disustituidas en 1,3 como amtagonistas de adrenorreceptor alfa-2. | |
| JP5850589B2 (ja) | フェニル−３−アザ−ビシクロ［３．１．０］ヘキサ−３−イル−メタノン及び薬物としてのこれらの使用 | |
| JP2009525296A (ja) | インテグリン阻害化合物およびその使用 | |
| AU2015335694A1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| CN101538244A (zh) | 具有cb1激动活性,cb1部分激动活性或cb1拮抗活性的1h-咪唑衍生物 | |
| BG100040A (bg) | Индолови производни като 5-нт1а и/или 5-нт2 лиганди | |
| JP2003523996A (ja) | ２−オキソ−１−ピロリジン誘導体、それらの製造方法及びそれらの使用 | |
| CA2401502A1 (en) | Carboxylic acid derivatives as ip antagonists | |
| JP2008506744A (ja) | α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用 | |
| KR20110031318A (ko) | Ｉａ 심부전 및 암 치료에 유용한 단백질 키나제 ｄ 억제제로서의 2,4'-비피리디닐 화합물 | |
| CN102395588A (zh) | 杂环化合物、包含它们的药物组合物及其作为甘氨酸转运蛋白1的抑制剂的用途 | |
| JP2010516635A5 (es) | ||
| NO310236B1 (no) | Nye 2,3-diokso-1,2,3,4-tetrahydro-quinoksalinylderivater og farmasöytisk sammensetning omfattende samme | |
| CA2396277A1 (en) | Condensed azepines as vasopressin agonists | |
| US6818655B2 (en) | Urotensin-II receptor antagonists | |
| JP2008538357A (ja) | 薬学的に活性なジアゼパン | |
| Breslin et al. | Non-Peptide αvβ3 antagonists. Part 6: Design and synthesis of αvβ3 antagonists containing a pyridone or pyrazinone central scaffold | |
| WO2014060328A1 (en) | 6-aminoindole derivatives as trp channel antagonists | |
| JP2016199575A (ja) | 新規ベンゾアゼピン誘導体及びその医薬用途 | |
| PE20001463A1 (es) | Nuevos derivados de piperidina, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen | |
| TW200846328A (en) | GlyT1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders | |
| US5376748A (en) | Nitroquinolone derivatives | |
| HUT74091A (en) | 1,5-benzodiazepine derivatives having cck and/or gastrin antagonistic activity |